A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina

Merck KGaA (EMD Serono)

Status: Completed

Conditions: Multiple Sclerosis, Relapsing-remitting

Study type: Observational

Funder types: Industry

Identifiers

NCT01080001

EMR 200077-506

Details and patient eligibility

About

This is an observational, non-controlled, multicentric, prospective study planned to be conducted in 66 subjects diagnosed with multiple sclerosis (MS) in 20 centres of Argentina. Fatigue is recognized as one of the most frequent symptoms of MS with a high incidence in MS subjects. The link between fatigue and the degree of disability and other manifestations of the disease, such as depression has not been yet clearly understood. Hence, this study aims to understand the way in which fatigue impairs the quality of life (QoL) of MS subjects. This epidemiologic study can contribute to a better understanding of the way in which fatigue correlates with depression and the intensity with which both situations impact on the QoL of MS subjects.

Full description

Fatigue is recognized as one of the most frequent symptoms of MS and its impact on QoL of subjects is high. Fatigue in MS is sometimes considered as a prodromic symptom or as a peculiar symptom that must be differentiated from natural fatigue, pathological fatigue of other chronic diseases; as well as from fatigue caused by the excessive effort in case of gait disorder, spasticity or paresis. The origin of the fatigue symptom in MS is unknown and the cause is likely to be multifactorial. The evaluation of the fatigue is challenging, due to its variability and hence, scales such as Krupp's Fatigue Severity Scale (FSS) has been developed for measuring MS fatigue.

OBJECTIVES

Primary objective:

• To determine the impact of fatigue on QoL of MS subjects in Argentina

Secondary objective:

• To evaluate correlation between FSS and disability, depression, demographic variables; and between FSS and the use of disease modifying drugs
• To determine the impact of depression and neurological disability on QoL of MS subjects in Argentina

The subjects will be managed with the clinical and therapeutic elements that the treating doctor considers appropriate, without modifying their decisions due to the subject inclusion into the study. The epidemiologic data required by this study will be collected by the investigator from the documents in which each subject visit is registered, whether programmed or not. Once the recruiting period of 12 months is over, the collection of data will continue during the full 24 months period for each subject. The closure of the study will be marked by the follow-up of the last subject who entered the study.

Enrollment: 71 patients

Sex: All

Ages: 21 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with MS diagnosis (McDonald's criteria) in its relapsing remitting form
• Subjects between 21-60 years of age
• Subjects who did not have relapses during the 3 months before the inclusion
• Subjects with more than 1 year since the MS diagnosis or with a clinically defined MS

Exclusion criteria

• Subjects with life expectancy of less than 5 years at the moment of inclusion
• Subjects with other associated neurological disease
• Subjects with psychiatric diseases
• Subjects who have familiar antecedents (first grade) of severe depression
• Subjects with alcohol or drug abuse
• Subjects who are pregnant
• Subjects with FSS between 4 and 5
• Subjects who have used anxiolytics and anti depressants that could affect the fatigue symptoms during the 3 months before the inclusion